赛升药业：2025年前三季度净利润约5186万元

Company Performance - Sai Sheng Pharmaceutical reported a revenue of approximately 309 million yuan for the first three quarters of 2025, a year-on-year decrease of 4.41% [1] - The net profit attributable to shareholders was approximately 51.86 million yuan, reflecting a year-on-year increase of 152.81% [1] - Basic earnings per share increased to 0.11 yuan, marking a year-on-year growth of 155% [1] Market Context - As of the report date, Sai Sheng Pharmaceutical has a market capitalization of 5.8 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2] - The secondary market for biopharmaceuticals is experiencing a surge, while the primary market is facing challenges in fundraising [2]